A case report on gonadal dysgenesis caused by a rare NR5A1-associated contiguous gene deletion: a diagnostic challenge
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20260582Keywords:
Gonadal dysgenesis, NR5A1 mutation, Primary amenorrhoea, 46, XY disorder of sex developmentAbstract
Disorders of sexual development (DSD) encompass a diverse group of congenital conditions characterised by atypical development of chromosomal, gonadal, or anatomical sex. Among these, NR5A1 mutations represent an important and heterogeneous cause of 46, XY DSD, often exhibiting wide phenotypic variability with limited genotype–phenotype correlation. Early incorporation of genetic testing is therefore pivotal, particularly when gonadal dysgenesis is suspected. We present a 19-year-old individual, raised as female, who presented with primary amenorrhoea and underdeveloped secondary sexual characteristics. Endocrine testing showed hypergonadotropic hypogonadism, and karyotyping identified a genotype of 46, XY. Genetic testing revealed a contiguous deletion involving the NR5A1 gene, consistent with severe gonadal dysgenesis. Pelvic magnetic resonance imaging showed the presence of an infantile uterus, but, on diagnostic laparoscopy, complete Müllerian agenesis was discovered. Bilateral gonadectomy showed dysgenetic testes without signs of malignancy. This case highlights the diagnostic complexity of NR5A1-related DSD, the potential discordance between imaging and operative findings, and the importance of a multidisciplinary approach to ensure accurate diagnosis and appropriate management.
References
Lee PA, Houk CP, Ahmed SF, Hughes IA. Consensus statement on management of intersex disorders. Pediatrics. 2006;118(2):e488-500. DOI: https://doi.org/10.1542/peds.2006-0738
Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT. Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development. Best Pract Res Clin Endocrinol Metab. 2007;21(3):351-65. DOI: https://doi.org/10.1016/j.beem.2007.06.003
Köhler B, Lin L, Ferraz-de-Souza B, Wieacker P, Heidemann P, Schroeder V, et al. Five novel mutations in steroidogenic factor-1 (NR5A1) causing 46, XY patients with severe underandrogenization but without adrenal insufficiency. Hum Mutat. 2008;29(1):59-64. DOI: https://doi.org/10.1002/humu.20588
Bashamboo A, McElreavey K. NR5A1 mutations in disorders of sex development. Sex Dev. 2016;10(1):1-9. DOI: https://doi.org/10.1159/000452637
Ferraz-de-Souza B, Lin L, Achermann JC. Steroidogenic factor-1 (SF-1, NR5A1) and human disease. Mol Cell Endocrinol. 2011;336(2):198-205. DOI: https://doi.org/10.1016/j.mce.2010.11.006
Camats N, Fernández-Cancelo G, Audí L, Schaller A, Flück CE. Broad phenotypic spectrum in 46, XY disorders of sex development associated with NR5A1 gene deletions. Clin Endocrinol (Oxf). 2018;89(3):376-84.
Ahmed SF, Achermann JC, Arlt W, Balen A, Conway G, Edwards Z, et al. UK guidance on the initial evaluation of an infant or adolescent with a suspected disorder of sex development. Clin Endocrinol (Oxf). 2016;84(5):771-88. DOI: https://doi.org/10.1111/cen.12857
Ahmed SF, Bryce J, Hiort O, Hunter I, Ahmed M, Cheng A, et al. International consensus on the management of disorders/differences of sex development in adolescence and adulthood. Eur J Endocrinol. 2021;185(3):P1-29.
Cools M, Looijenga LHJ, Wolffenbuttel KP, T’Sjoen G. Managing germ cell cancer risk in disorders of sex development patients. Endocr Rev. 2021;42(4):410-42.
Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, et al. Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1. Nat Genet. 1999;22(2):125–126. DOI: https://doi.org/10.1038/9629
Alhamoudi KM, Alghamdi B, Aljomaiah A, Alswailem M, Al-Hindi H, Alzahrani AS. Case report: severe gonadal dysgenesis causing 46, XY disorder of sex development due to a novel NR5A1 variant. Front Genet. 2022;13:885589. DOI: https://doi.org/10.3389/fgene.2022.885589
Bashamboo A, Ferraz-de-Souza B, Lourenço D, Lin L, Schlaff WD, Achermann JC, et al. Human disorders of sex development: genetics, phenotypes, and management. Endocr Rev. 2022;43(3):347-87.